Over the past 25+ years, Dr. Sastry has conducted research in the broad areas of viral oncology and immunology focuses on understanding the biology, pathology and genetics of two viral diseases impacting human health: HPV-associated cancers and HIV-induced AIDS. The overall goal of his research is to develop procedures and reagents for prediction, treatment as well as prevention. His research program has been continuously supported by funds from NIH, sponsored research, and philanthropy. Some of his laboratory's most notable findings are the identification and patenting of HPV-16 E6/E7 peptides, for which women disease-free after treatment for HPV-CIN exhibited T cell immunity and the design of effective mucosal vaccination strategies to deliver them. Continuing work in this area seeks to combine peptide vaccination with other immune therapies such as 4-1BB agonists and CTLA-4 blockade to eradicate HPV-derived cancers. His lab developed a synthetic peptide-cocktail vaccine based on highly conserved sequences within the envelope protein of HIV-1 that proved effective against AIDS development and, in collaboration studies, demonstrated that recombinant adenoviral constructs expressing the peptide cocktail as well as full-length HIV envelope induce protective immunity against mucosal viral challenge, the most prevalent route of HIV transmission worldwide.
Publications/Creative Works
Click here to search for this faculty member's publications on PubMed.
Important Disclaimer: The responsibility for the accuracy of the information contained on these pages lies with the authors and user providing such information.